amivantamab + lazertinib + carboplatin + pemetrexed

This is a **four-drug combination regimen** consisting of *amivantamab* (a fully human bispecific monoclonal antibody targeting EGFR and MET), *lazertinib* (an oral, third-generation EGFR tyrosine kinase inhibitor), *carboplatin* (a platinum-based chemotherapy agent), and *pemetrexed* (an antifolate chemotherapy agent). The combination is approved for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations, including EGFR exon 19 deletions, exon 21 L858R, and exon 20 insertions[1]. Amivantamab targets and blocks EGFR and MET receptor signaling, disrupting oncogenic pathways and engaging immune cell responses. Lazertinib selectively inhibits mutant EGFR signaling. Carboplatin causes DNA cross-linking and cell death. Pemetrexed inhibits nucleotide biosynthesis, suppressing DNA/RNA synthesis in cancer cells. The regimen is supported by pivotal clinical trial data demonstrating superior progression-free survival and overall response rates in NSCLC patients[1][4][6].

Brand names

Rybrevant (amivantamab)Lazcluze (lazertinib)Paraplatin (carboplatin)Alimta (pemetrexed)

Other names

amivantamab + lazertinib + carboplatin + pemetrexed